Back to Search
Start Over
Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice
- Source :
- Antiviral research. 120
- Publication Year :
- 2015
-
Abstract
- Long acting nanoformulated antiretroviral therapy (nanoART) can sustain plasma drug levels and improve its biodistribution. Cell targeted-nanoART can achieve this and bring drug efficiently to viral reservoirs. However, if such improvements affect antiretroviral responses remains unknown. To these ends, we tested folic acid (FA)-linked poloxamer407 coated-ritonavir boosted atazanavir (FA-nanoATV/r) nanoparticles for their ability to affect chronic HIV-1 infection in humanized mice. Following three every other week 100 mg/kg FA-nanoATV/r intramuscular injection administered to infected animals viral RNA was at or below the detection limit, cell-associated HIV-1p24 reduced and CD4+ T cell counts protected. The dosing regimen improved treatment outcomes more than two fold from what was reported for untargeted nanoATV/r. We posit that these nanoformulations have potential for translation to human use.
- Subjects :
- Drug
media_common.quotation_subject
Atazanavir Sulfate
HIV Infections
Mice, SCID
Poloxamer
Pharmacology
Injections, Intramuscular
Article
Folic Acid
Pharmacokinetics
Virology
medicine
Animals
Humans
media_common
Drug Carriers
Ritonavir
Nanoart
business.industry
Folate Receptors, GPI-Anchored
Viral Load
Atazanavir
CD4 Lymphocyte Count
Nanomedicine
Treatment Outcome
Anti-Retroviral Agents
Pharmacodynamics
Delayed-Action Preparations
Nanoparticles
RNA, Viral
business
Viral load
medicine.drug
Subjects
Details
- ISSN :
- 18729096
- Volume :
- 120
- Database :
- OpenAIRE
- Journal :
- Antiviral research
- Accession number :
- edsair.doi.dedup.....22c58fd81a0396067505413650c7231d